BID, BH3 interacting domain death agonist, 637

N. diseases: 117; N. variants: 5
Disease: Liver carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.320 Biomarker disease BEFREE Eligible patients with no prior systemic therapy for advanced HCC and Child-Pugh A to B7 were treated with sorafenib 400 mg BID and escalating doses of cixutumumab (2, 4, or 6 mg/kg IV weekly) in a 3 + 3 design. 29520435 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.320 Biomarker disease BEFREE The RP2D was tivantinib 360 mg BID and sorafenib 400 mg BID for all cancer histologies, except in hepatocellular carcinoma (HCC) patients tivantinib was 240 mg BID plus sorafenib 400 mg BID. 25294187 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.320 Biomarker disease CTD_human Bid sensitizes apoptosis induced by chemotherapeutic drugs in hepatocellular carcinoma. 15289866 2004